Glioblastoma: Causes, Symptoms, Diagnosis, Treatment, and Prognosis

~Introduction

Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive and common malignant primary brain tumor in adults. Classified as a Grade IV astrocytoma by the World Health Organization (WHO), glioblastoma is characterized by rapid growth, extensive infiltration into surrounding brain tissue, and resistance to conventional therapies. Despite advances in neurosurgery, radiation therapy, and chemotherapy, glioblastoma remains one of the most challenging cancers to treat, with a poor overall prognosis.

This comprehensive article explores glioblastoma in detail, covering its causes, risk factors, symptoms, diagnostic methods, treatment options, recent advances, prognosis, and ongoing research.

~What Is Glioblastoma?

Glioblastoma is a high-grade malignant tumor that arises from astrocytes, star-shaped glial cells that support nerve cells in the brain. It can develop anywhere in the central nervous system but most commonly occurs in the cerebral hemispheres, particularly the frontal and temporal lobes.

Key characteristics of glioblastoma include:

• Extremely fast tumor growth

• Extensive invasion into normal brain tissue

• Formation of abnormal blood vessels

• Areas of necrosis (dead tumor tissue)

• High recurrence rate after treatment

Glioblastoma can occur at any age but is most frequently diagnosed in adults aged 45–70 years.

~Types of Glioblastoma

Glioblastoma is broadly divided into two main types:

1. Primary (De Novo) Glioblastoma

• Accounts for about 90% of cases

• Develops rapidly without evidence of a pre-existing lower-grade tumor

• More common in older adults

• Often associated with EGFR amplification and PTEN mutations

2. Secondary Glioblastoma

• Evolves from a lower-grade astrocytoma

• Occurs more frequently in younger patients

• Associated with IDH1 or IDH2 mutations

• Slightly better prognosis compared to primary GBM

~Causes and Risk Factors of Glioblastoma

The exact cause of glioblastoma remains unknown. However, several genetic and environmental factors have been linked to its development.

Genetic Factors

• IDH mutations

• TP53 gene mutations

• EGFR gene amplification

• Loss of chromosome 10

These mutations lead to uncontrolled cell growth, impaired DNA repair, and resistance to cell death.

Environmental and Lifestyle Risk Factors

• Ionizing radiation exposure (especially during childhood)

• Rare genetic syndromes such as:

  • Li-Fraumeni syndrome

  • Neurofibromatosis type 1

  • Turcot syndrome

There is no strong evidence linking glioblastoma to mobile phone use, diet, smoking, or alcohol consumption.

~Signs and Symptoms of Glioblastoma

Symptoms of glioblastoma depend on the tumor’s size, growth rate, and location in the brain. Because the tumor grows rapidly, symptoms often worsen quickly.

Common Symptoms

• Persistent or worsening headaches

• Seizures (often the first symptom)

• Nausea and vomiting

• Cognitive decline and memory loss

• Personality or behavioral changes

• Difficulty speaking or understanding language

• Weakness or paralysis on one side of the body

• Visual disturbances

Advanced Symptoms

• Increased intracranial pressure

• Loss of consciousness

• Severe neurological deficits

Early detection is difficult because initial symptoms may resemble common neurological conditions.

~Diagnosis of Glioblastoma

Accurate diagnosis of glioblastoma involves a combination of clinical evaluation, imaging studies, and pathological confirmation.

1. Neurological Examination

A detailed neurological assessment helps identify deficits related to brain function, such as motor weakness, speech problems, or sensory loss.

2. Imaging Studies

• Magnetic Resonance Imaging (MRI) with contrast is the gold standard

• Glioblastoma typically appears as a ring-enhancing lesion with central necrosis

• CT scans may be used in emergencies

3. Biopsy and Histopathology

A surgical biopsy or tumor resection confirms the diagnosis. Histological features include:

• Cellular pleomorphism

• High mitotic activity

• Necrosis

• Microvascular proliferation

4. Molecular Testing

Molecular markers such as IDH mutation status, MGMT promoter methylation, and TERT mutations help guide treatment and prognosis.

~Treatment Options for Glioblastoma

Glioblastoma treatment requires a multimodal approach involving surgery, radiation, and chemotherapy. The goal is to prolong survival, relieve symptoms, and maintain quality of life.

1. Surgical Resection

• Maximum safe surgical removal is the first step

• Complete removal is usually impossible due to tumor infiltration

• Extent of resection significantly impacts survival

2. Radiation Therapy

• Standard treatment includes external beam radiation therapy

• Typically delivered over 6 weeks

• Targets residual tumor cells after surgery

3. Chemotherapy

• Temozolomide is the standard chemotherapy drug

• Given concurrently with radiation and as adjuvant therapy

• Patients with MGMT promoter methylation respond better

4. Tumor Treating Fields (TTF)

• A non-invasive therapy using alternating electric fields

• Disrupts cancer cell division

• Approved as an adjunct therapy for newly diagnosed GBM

~Emerging and Experimental Therapies

Ongoing research aims to improve glioblastoma outcomes through innovative treatments.

Immunotherapy

• Immune checkpoint inhibitors

• Cancer vaccines

• CAR-T cell therapy (experimental)

Targeted Therapy

• Drugs targeting EGFR and other molecular pathways

• Limited success so far due to tumor heterogeneity

Gene and Viral Therapy

• Oncolytic viruses designed to kill tumor cells

• Early clinical trials show promise

Clinical Trials

Participation in clinical trials is encouraged, as standard therapies have limited long-term effectiveness.

~Prognosis and Survival Rate

Glioblastoma has a poor prognosis despite aggressive treatment.

Survival Statistics

• Median survival: 12–15 months

• 2-year survival rate: ~25%

• 5-year survival rate: <10%

Factors Affecting Prognosis

• Age at diagnosis

• Performance status

• Extent of surgical resection

• Molecular markers (IDH mutation, MGMT methylation)

• Response to therapy

Patients with secondary glioblastoma and favorable molecular profiles generally have better outcomes.

~Quality of Life and Supportive Care

Managing symptoms and maintaining quality of life are critical components of glioblastoma care.

Supportive Treatments

• Corticosteroids to reduce brain swelling

• Anti-seizure medications

• Physical and occupational therapy

• Cognitive rehabilitation

Palliative Care

Early palliative care improves symptom management, emotional support, and patient well-being.

~Living With Glioblastoma

A glioblastoma diagnosis can be emotionally overwhelming for patients and families. Psychological support, counseling, and patient advocacy groups play a vital role in coping with the disease.

Caregivers should be educated about:

• Symptom monitoring

• Medication management

• End-of-life planning when appropriate

~Prevention and Screening

There are currently no proven methods to prevent glioblastoma. Routine screening is not recommended for the general population due to the rarity and aggressive nature of the disease.

~Future Directions in Glioblastoma Research

Research is focused on:

• Personalized medicine

• Improved drug delivery across the blood-brain barrier

• Combination therapies

• Artificial intelligence in diagnosis and treatment planning

Advances in molecular biology and immunotherapy offer hope for better outcomes in the future.

~Conclusion

Glioblastoma is one of the most aggressive and deadly brain tumors, posing significant challenges for patients and healthcare providers. Despite limited survival rates, advancements in surgery, radiation, chemotherapy, and emerging therapies continue to improve symptom control and extend survival for some patients.

Ongoing research, early diagnosis, multidisciplinary care, and access to clinical trials remain essential in the fight against glioblastoma. Increased awareness and continued innovation are critical to improving outcomes for this devastating disease.